- GSK Plc's GSK Q2 turnover reached £6.9 billion, up 19% Y/Y on the actual exchange rate (AER) and 13% on a constant exchange rate (CER) basis.
- Specialty Medicines turnover was £2.7 billion, up 44% AER, 35% CER, driven by consistent growth in all therapy areas, including sales of Xevudy.
- Sales of Xevudy (sotrovimab) for COVID-19 treatment stood at £466 billion.
- Related: GSK Completes Spin-Off Of Its Consumer Healthcare Business.
- Vaccines sales benefited from Shingrix's post-pandemic recovery and reached £1.72 billion, up 31% at AER, and 24% at CER, excluding unrepeated 2021 pandemic adjuvant sales. Shingrix generated £731 million in sales.
- General Medicines sales reached £2.5 billion, up 5% AER and 2% CER reflecting growth from Trelegy and recovery of the antibiotics market.
- The adjusted operating margin of 29% is 0.9 percentage points higher at AER and 1.5 percentage points lower on a CER basis than in Q1 2021. reflecting the impact of low margin COVID-19 solutions sales (Xevudy).
- Adjusted EPS was 34.7p compared to 28.2p a year ago.
- However, the company's pandemic solutions sales have taken a hit, and GSK said that expected 2022 sales had largely been achieved in the first half of this year.
- Outlook: GSK raised FY22 sales growth to 6% - 8%, compared to the previous guidance of 5% - 7%, and adjusted operating profit to increase by 13% - 15% (prior 12% - 14%).
- Price Action: GSK shares are up 0.66% at $42.80 during the premarket session on the last check Wednesday.
- Photo via Wikimedia Commons
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
